Drug Profile

BT 1501

Alternative Names: BT-1501

Latest Information Update: 04 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Texas Southwestern Medical Center
Developer Barricade Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action EBP protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Colorectal cancer

Most Recent Events

04 Dec 2025 Barricade Therapeutics plans a phase I trial in Colorectal cancer in 2025.
28 Nov 2025 Preclinical trials in Colorectal cancer in USA (PO) (Barricade Therapeutics pipeline, November 2025)
28 Nov 2025 Pharmacodynamics data from a preclinical study for Colorectal cancer released by Barricade Therapeutics (Barricade Therapeutics website, November 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com